José Manuel Casas Rojo

Dr. José Manuel Casas Rojo

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2020 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Closed access
Jose-Manuel Ramos-RinconJose-Manuel Ramos-Rincon
Jose-Manuel Ramos-Rincon
VBVerónica Buonaiuto
Verónica Buonaiuto
MRMichele Ricci
Michele Ricci
JMJesica Martín-Carmona
Jesica Martín-Carmona
DPDiana Paredes-Ruíz
Diana Paredes-Ruíz
SNSemi-Covid-19 Network
Semi-Covid-19 Network
Background: Advanced age is a well-known risk factor for poor prognosis in COVID-19. However, few studies have specifically focused on very old inpatients with COVID-19. This study aims to describe the clinical characteristics of very old inpatients with COVID-19 and identify risk factors for in-hospital mortality at admission. Methods: We conducted a nationwide, multicenter, retrospective, observational study in patients ≥ 80 years hospitalized with COVID-19 in 150 Spanish hospitals (SEMI-COVID-19) Registry (March 1–May 29, 2020). The primary outcome was in-hospital mortality. A uni- and multivariate logistic regression was performed to assess predictors of mortality at admission. Results: A total of 2772 consecutive patients (49.4% men, median age 86.3 years) were analyzed. Rates of atherosclerotic cardiovascular disease, diabetes mellitus, dementia, and Barthel Index < 60 were 30.8%, 25.6%, 30.5%, and 21.0%, respectively. The overall case-fatality rate was 46.9% (n: 1301) and increased with age (80–84 years: 41.6%; 85–90 years: 47.3%; 90–94 years: 52.7%; ≥95 years: 54.2%). After analysis, male sex and moderate-to-severe dependence were independently associated with in-hospital mortality; comorbidities were not predictive. At admission, independent risk factors for death were: oxygen saturation < 90%; temperature ≥ 37.8°C; quick sequential organ failure assessment (qSOFA) score ≥ 2; and unilateral–bilateral infiltrates on chest x-rays. Some analytical findings were independent risk factors for death, including estimated glomerular filtration rate < 45 mL/min/1.73 m2; lactate dehydrogenase ≥ 500 U/L; C-reactive protein ≥ 80 mg/L; neutrophils ≥ 7.5 × 103/μL; lymphocytes < 0.8 × 103/μL; and monocytes < 0.5 × 103/μL. Conclusions: This first large, multicenter cohort of very old inpatients with COVID-19 shows that age, male sex, and poor preadmission functional status—not comorbidities—are independently associated with in-hospital mortality. Severe COVID-19 at admission is related to poor prognosis.

8 April 2022 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
MRManuel Rubio-Rivas
Manuel Rubio-Rivas
JMJosé María Mora-Luján
José María Mora-Luján
FFFrancesc Formiga
Francesc Formiga
CACoral Arévalo-Cañas
Coral Arévalo-Cañas
JRJuan Manuel Lebrón Ramos
Juan Manuel Lebrón Ramos
JRJosé Manuel Casas Rojo
José Manuel Casas Rojo

11 May 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJorge Calderón-Parra
Jorge Calderón-Parra
AMAntonio Muiño-Miguez
Antonio Muiño-Miguez
ABAlejandro D. Bendala-Estrada
Alejandro D. Bendala-Estrada
ARAntonio Ramos-Martínez
Antonio Ramos-Martínez
EMElena Muñez-Rubio
Elena Muñez-Rubio
JNJesús Millán Núñez-Cortés
Jesús Millán Núñez-Cortés
Background: Most patients with COVID-19 receive antibiotics despite the fact that bacterial co-infections are rare. This can lead to increased complications, including antibacterial resistance. We aim to analyze risk factors for inappropriate antibiotic prescription in these patients and describe possible complications arising from their use. Methods: The SEMI-COVID-19 Registry is a multicenter, retrospective patient cohort. Patients with antibiotic were divided into two groups according to appropriate or inappropriate prescription, depending on whether the patient fulfill any criteria for its use. Comparison was made by means of multilevel logistic regression analysis. Possible complications of antibiotic use were also identified. Results: Out of 13,932 patients, 3047 (21.6%) were prescribed no antibiotics, 6116 (43.9%) were appropriately prescribed antibiotics, and 4769 (34.2%) were inappropriately prescribed antibiotics. The following were independent factors of inappropriate prescription: February-March 2020 admission (OR 1.54, 95%CI 1.18–2.00), age (OR 0.98, 95%CI 0.97–0.99), absence of comorbidity (OR 1.43, 95%CI 1.05–1.94), dry cough (OR 2.51, 95%CI 1.94–3.26), fever (OR 1.33, 95%CI 1.13–1.56), dyspnea (OR 1.31, 95%CI 1.04–1.69), flu-like symptoms (OR 2.70, 95%CI 1.75–4.17), and elevated C-reactive protein levels (OR 1.01 for each mg/L increase, 95% CI 1.00–1.01). Adverse drug reactions were more frequent in patients who received ANTIBIOTIC (4.9% vs 2.7%, p < .001). Conclusion: The inappropriate use of antibiotics was very frequent in COVID-19 patients and entailed an increased risk of adverse reactions. It is crucial to define criteria for their use in these patients. Knowledge of the factors associated with inappropriate prescribing can be helpful.

28 September 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Enrique RodillaEnrique Rodilla
Enrique Rodilla
ASAlberto Saura
Alberto Saura
IJIratxe Jiménez
Iratxe Jiménez
AMAndrea Mendizábal
Andrea Mendizábal
APAraceli Pineda-Cantero
Araceli Pineda-Cantero
RHRicardo Gómez Huelgas
Ricardo Gómez Huelgas
It is unclear to which extent the higher mortality associated with hypertension in the coronavirus disease (COVID-19) is due to its increased prevalence among older patients or to specific mechanisms. Cross-sectional, observational, retrospective multicenter study, analyzing 12226 patients who required hospital admission in 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics of survivors versus non-survivors. The mean age of the study population was 67.5 ± 16.1 years, 42.6% were women. Overall, 2630 (21.5%) subjects died. The most common comorbidity was hypertension (50.9%) followed by diabetes (19.1%), and atrial fibrillation (11.2%). Multivariate analysis showed that after adjusting for gender (males, OR: 1.5, p = 0.0001), age tertiles (second and third tertiles, OR: 2.0 and 4.7, p = 0.0001), and Charlson Comorbidity Index scores (second and third tertiles, OR: 4.7 and 8.1, p = 0.0001), hypertension was significantly predictive of all-cause mortality when this comorbidity was treated with angiotensin-converting enzyme inhibitors (ACEIs) (OR: 1.6, p = 0.002) or other than renin-angiotensin-aldosterone blockers (OR: 1.3, p = 0.001) or angiotensin II receptor blockers (ARBs) (OR: 1.2, p = 0.035). The preexisting condition of hypertension had an independent prognostic value for all-cause mortality in patients with COVID-19 who required hospitalization. ARBs showed a lower risk of lethality in hypertensive patients than other antihypertensive drugs.

8 November 2021 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
AEAlejandro David Bendala Estrada
Alejandro David Bendala Estrada
JCJorge Calderón-Parra
Jorge Calderón-Parra
ECEduardo Fernández Carracedo
Eduardo Fernández Carracedo
AMAntonio Muiño Míguez
Antonio Muiño Míguez
ARAntonio Ramos-Martínez
Antonio Ramos-Martínez
JNJesús Millán Núñez-Cortés
Jesús Millán Núñez-Cortés
Background: Since December 2019, the COVID-19 pandemic has changed the concept of medicine. This work aims to analyze the use of antibiotics in patients admitted to the hospital due to SARS-CoV-2 infection.Methods: This work analyzes the use and effectiveness of antibiotics in hospitalized patients with COVID-19 based on data from the SEMI-COVID-19 registry, an initiative to generate knowledge about this disease using data from electronic medical records. Our primary endpoint was all-cause in-hospital mortality according to antibiotic use. The secondary endpoint was the effect of macrolides on mortality.Results: Of 13,932 patients, antibiotics were used in 12,238. The overall death rate was 20.7% and higher among those taking antibiotics (87.8%). Higher mortality was observed with use of all antibiotics (OR 1.40, 95% CI 1.21–1.62;p < .001) except macrolides, which had a higher survival rate (OR 0.70, 95% CI 0.64–0.76;p < .001). The decision to start antibiotics was influenced by presence of increased inflammatory markers and any kind of infiltrate on an x-ray. Patients receiving antibiotics required respiratory support and were transferred to intensive care units more often.Conclusions: Bacterial co-infection was uncommon among COVID-19 patients, yet use of antibiotics was high. There is insufficient evidence to support widespread use of empiric antibiotics in these patients. Most may not require empiric treatment and if they do, there is promising evidence regarding azithromycin as a potential COVID-19 treatment.

1 November 2020 in Revista Clínica Española (English Edition)
Verified
Journal Article
Closed access
JRJosé Manuel Casas Rojo
José Manuel Casas Rojo
JAJ.M. Antón-Santos
J.M. Antón-Santos
JMJ. Millán-Núñez-Cortés
J. Millán-Núñez-Cortés
CLC. Lumbreras-Bermejo
C. Lumbreras-Bermejo
JRJ.M. Ramos-Rincón
J.M. Ramos-Rincón
RGR. Gómez-Huelgas
R. Gómez-Huelgas